Francesco De Lazzaro

Dr. Francesco De Lazzaro


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
FLFrancesco De Lazzaro
Francesco De Lazzaro
FAFrancesco Alessandri
Francesco Alessandri
MTMaria Grazia Tarsitano
Maria Grazia Tarsitano
FBFederico Bilotta
Federico Bilotta
FPFrancesco Pugliese
Francesco Pugliese

Verified
Journal Article
Open access
PDF file
Francesco AlessandriFrancesco Alessandri
Francesco Alessandri
ATAntonella Tosi
Antonella Tosi
FLFrancesco De Lazzaro
Francesco De Lazzaro
CAChiara Andreoli
Chiara Andreoli
ACAndrea Cicchinelli
Andrea Cicchinelli
OGon behalf of the Policlinico Umberto I COVID-19 Group
on behalf of the Policlinico Umberto I COVID-19 Group
(1) Background: the aim of this study was to create a score to predict the incidence of CPAP failure in COVID-19 patients early. (2) Methods: in this retrospective observational study, we included all consecutive adult patients admitted between February and April 2021. The main outcome was the failure of CPAP support (intubation or death). (3) Results: two-hundred and sixty-three COVID-19 patients were managed with CPAP. The population was divided in short-CPAP (CPAP days ≤ 10; 72.6%) and long-CPAP (>10; 27.4%) groups. After balancing the entire population using a stabilized IPTW method, we applied a multivariable logistic regression analysis to identify the risk factors for CPAP failure. We used the identified covariates to create a mathematical model, the CPAP Failure Score (CPAP-FS). The multivariable logistic regression analysis identified four variables: SpO2 (OR = 0.86; p-value = 0.001), P/F ratio (OR = 0.99; p-value = 0.008), the Call Score (OR = 1.44; p-value = 0.02), and a pre-existing chronic lung disease (OR = 3.08; p-value = 0.057). The beta-coefficients obtained were used to develop the CPAP-FS, whose diagnostic ability outperformed other relevant COVID-19-related parameters (AUC = 0.87; p-value < 0.0001). We validated the CPAP-FS using a 10-fold internal cross-validation method which confirmed the observed results (AUCs 0.76–0.80; p-values < 0.0001). (4) Conclusions: the CPAP-FS can early identify COVID-19 patients who are at risk of CPAP failure.